



For Immediate Release

September 29, 2022

Acuitas President & CEO, Dr. Thomas Madden, Receives BIOTECanada Award for Game Changing Leadership

Vancouver, B.C. – Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, has received BIOTECanada’s 2022 Gold Leaf Award in the Game Changing Industry Leadership category. The Gold Leaf Awards celebrate innovation and entrepreneurship within the Canadian biotech industry across all industry categories including health, agricultural, industrial and environmental biotechnology.

“It is always an honour to be recognized by a respected organization such as BIOTECanada. Acuitas is focused on developing lipid nanoparticle delivery systems for nucleic acid therapeutics, and I am grateful for the innovation, creativity and dedication of the Acuitas team,” said Dr. Madden. “Playing a crucial role in the development of the Pfizer/BioNTech COVID-19 vaccine COMIRNATY® is, of course, a huge achievement. We are incredibly proud of our work in helping to stem the global pandemic. This vaccine – which has had close to four billion doses distributed to 180 countries around the world – has showcased the safety and efficacy of mRNA.” He added: “Improving human health – helping people to live healthier lives – is what drives us at Acuitas. Game changing leadership, to me, comes from collaboration and connection – within Acuitas and in the biotech industry in Canada. We are committed to supporting our industry colleagues, providing training opportunities for those just starting their careers, and encouraging young people to consider careers in STEM. Helping to build and grow a thriving and values-based biotech sector in Canada is a goal for everyone at Acuitas. I am immensely proud of that.”

About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY®, which has received full approval in



the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, tuberculosis, malaria, rabies and other serious diseases.

-END-